Sglt2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies

Endocrine Journal

Volumn 63, Issue 2, 2016, Pages 187-191

  Hayashi, Akinori ^a   Takano, Koji ^a   Kawai, Sayuki ^a   Shichiri, Masayoshi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous glucose monitoring; Insulin antibodies; Ipragliflozin; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

C PEPTIDE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HLA ANTIGEN; IMMUNOREACTIVE INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; IPRAGLIFLOZIN; MITOMYCIN; PIOGLITAZONE; SITAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; ALLELE; ANTIBODY COMBINING SITE; ANTIBODY TITER; ANUS CARCINOMA; AUTOIMMUNE DISEASE; BINDING AFFINITY; BLOOD GLUCOSE MONITORING; CANCER RADIOTHERAPY; CASE REPORT; DIET THERAPY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN AUTOIMMUNE SYNDROME; MALE; MIDDLE AGED; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ANTIBODIES; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84959375542     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0523     Document Type: Note

References (9)

1. Van Haeften TW, Krom BA, Gerich JE (1987) Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibodybinding kinetics. Diabetes Care 10: 160-163.
2. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, et al. (2007) Immunological responses to exogenous insulin. Endocr Rev 28: 625-652.
3. Radermecker RP, Renard E, Scheen AJ (2009) Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab Res Rev 25: 491-501.
4. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J (1997) Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report. Diabetes Care 20: 71-73.
5. Kawanami D, Ito T, Watanabe Y, Kinoshita J, Sakamoto M, et al. (2013) Successful control of a case of severe insulin allergy with liraglutide. J Diabetes Investig 4: 94-96.
6. Koyama R, Nakanishi K, Kato M, Yamashita S, Kuwahara H, et al. (2005) Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasma pheresis and prednisolone. Am J Med Sci 329: 259-264.
7. Chao EC, Henry RR (2010) SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559.
8. Hasan FM, Alsahli M, Gerich JE (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 104: 297-322.
9. Hirata Y, Uchigata Y (1994) Insulin autoimmune syndrome in Japan. Diabetes Res Clin Pract 24 Suppl: S153-157.